Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare Inc ownership filing shows Vanguard Capital Management beneficially owned 11,746,315 shares of common stock, representing 5.25% of the class as of 03/31/2026. The filing reports sole dispositive power for 11,746,315 shares and sole voting power for 1,567,953 shares. The Schedule 13G is signed on 04/30/2026 by Ashley Grim.
HCA Inc. is offering $3,000,000,000 aggregate principal amount of senior notes: $1,000,000,000 4.700% notes due May 15, 2031, $750,000,000 5.000% notes due May 15, 2033, and $1,250,000,000 5.300% notes due May 15, 2036. Interest on each series is payable semi‑annually on May 15 and November 15, beginning November 15, 2026.
HCA intends to use net proceeds (estimated at $2.975 billion) to redeem in full its outstanding $1.500 billion 5.250% notes due June 2026 and $1.000 billion 5.375% notes due September 2026 and for general corporate purposes, which may include repayment of commercial paper. The notes are senior unsecured obligations of HCA Inc. and are guaranteed on a senior unsecured basis by HCA Healthcare, Inc.
HCA Healthcare’s first quarter of 2026 showed steady growth with rising capital returns but a tougher payer mix. Revenue increased 4.3% to $19.109 billion, driven by a 1.1% rise in equivalent admissions and a 3.1% increase in revenue per equivalent admission. Net income attributable to HCA inched up to $1.620 billion, while diluted EPS rose to $7.15 from $6.45, helped by share repurchases that reduced diluted shares to 226.652 million.
Operating cash flow strengthened to $2.014 billion from $1.651 billion, supporting $1.119 billion of capital spending and $1.571 billion of share repurchases for 3.157 million shares. However, the cost of total uncompensated care grew to an estimated $1.252 billion from $1.055 billion as uninsured admissions climbed following the expiration of enhanced premium tax credits. Total debt reached $48.023 billion, much of it long term, and HCA continued its dividend program, with a $0.78 per-share quarterly dividend declared for payment in June 2026.
HCA Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on April 23, 2026. A total of 209,777,472 shares of common stock were represented in person or by proxy out of 223,568,966 shares outstanding and entitled to vote as of the record date.
Stockholders elected nine directors to one-year terms, with each nominee receiving more votes "For" than "Against." They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved a non-binding advisory resolution on named executive officer compensation, and two stockholder proposals—one requesting a report on healthcare consequences and another on shareholders’ right to act by written consent—did not receive sufficient support for approval.
HCA Healthcare, Inc. announced that its wholly owned subsidiary, HCA Inc., plans a public offering of senior unsecured notes, with final terms such as maturity, interest rate and principal amount to be set at pricing. The notes will be issued under an effective shelf registration.
HCA Inc. has given notice to redeem all $1.500 billion of its 5.250% senior notes due June 2026 and all $1.000 billion of its 5.375% senior notes due September 2026 on May 27, 2026, subject to receiving net proceeds from the new offering. HCA Inc. intends to use net proceeds for general corporate purposes, which may include repaying borrowings under its $4.000 billion commercial paper program and redeeming some or all of these 2026 notes.
HCA Healthcare, Inc. announced that its wholly owned subsidiary, HCA Inc., plans a public offering of senior unsecured notes, with final terms such as maturity, interest rate and principal amount to be set at pricing. The notes will be issued under an effective shelf registration.
HCA Inc. has given notice to redeem all $1.500 billion of its 5.250% senior notes due June 2026 and all $1.000 billion of its 5.375% senior notes due September 2026 on May 27, 2026, subject to receiving net proceeds from the new offering. HCA Inc. intends to use net proceeds for general corporate purposes, which may include repaying borrowings under its $4.000 billion commercial paper program and redeeming some or all of these 2026 notes.
HCA Inc. is offering multiple series of senior notes, each to be fully and unconditionally guaranteed on a senior unsecured basis by parent HCA Healthcare, Inc. The prospectus supplement states interest will be paid semi‑annually and the notes may be redeemed optionally; a Change of Control Triggering Event would permit holders to require repurchase at 101% plus accrued interest. Net proceeds are intended for general corporate purposes and may be used to repay commercial paper and to redeem some or all of the $1.500 billion 5.250% notes due June 2026 and the $1.000 billion 5.375% notes due September 2026. The document also discloses first quarter 2026 operating results: revenues of $19.109 billion, net income attributable to HCA Healthcare, Inc. of $1.620 billion and Adjusted EBITDA of $3.802 billion.
HCA Inc. is offering multiple series of senior notes, each to be fully and unconditionally guaranteed on a senior unsecured basis by parent HCA Healthcare, Inc. The prospectus supplement states interest will be paid semi‑annually and the notes may be redeemed optionally; a Change of Control Triggering Event would permit holders to require repurchase at 101% plus accrued interest. Net proceeds are intended for general corporate purposes and may be used to repay commercial paper and to redeem some or all of the $1.500 billion 5.250% notes due June 2026 and the $1.000 billion 5.375% notes due September 2026. The document also discloses first quarter 2026 operating results: revenues of $19.109 billion, net income attributable to HCA Healthcare, Inc. of $1.620 billion and Adjusted EBITDA of $3.802 billion.
HCA Healthcare, Inc. filed a shelf registration statement on Form S-3 to register offerings of common stock, preferred stock and debt securities and to permit resale of common stock by one or more selling stockholders "from time to time after the effective date of this registration statement."
The prospectus covers general terms for these securities and states the last reported NYSE sale price for HCA common stock was $432.46 per share on April 24, 2026. Specific offering amounts, prices and other terms will be provided in prospectus supplements.
HCA Healthcare, Inc. filed a shelf registration statement on Form S-3 to register offerings of common stock, preferred stock and debt securities and to permit resale of common stock by one or more selling stockholders "from time to time after the effective date of this registration statement."
The prospectus covers general terms for these securities and states the last reported NYSE sale price for HCA common stock was $432.46 per share on April 24, 2026. Specific offering amounts, prices and other terms will be provided in prospectus supplements.
HCA Healthcare, Inc. reported first quarter 2026 results showing modest growth and solid cash generation. Revenues rose 4.3% to $19.109 billion, while net income attributable to HCA increased 0.6% to $1.620 billion. Diluted earnings per share climbed 10.9% to $7.15, helped by share repurchases.
Adjusted EBITDA grew 1.9% to $3.802 billion, and cash flows from operating activities increased 22.0% to $2.014 billion. Management noted weaker seasonal respiratory volumes and weather-related impacts, largely offset by certain Medicaid supplemental program recognition.
The company continued significant capital deployment, with $1.119 billion in capital expenditures and repurchase of 3.157 million shares for $1.571 billion. The board declared a quarterly dividend of $0.78 per share, payable June 30, 2026. HCA reaffirmed its full-year 2026 guidance, including projected revenues of $76.5–$80.0 billion and Adjusted EBITDA of $15.55–$16.45 billion.
The Vanguard Group filed an Amendment No. 8 to Schedule 13G/A reporting zero beneficial ownership of HCA Healthcare Inc. common stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing lists 0 shares and 0% ownership and includes a signed certification by Ashley Grim, Head of Global Fund Administration.